Bliss GVS Pharma
175.92
-3.08(-1.72%)
Market Cap₹1,857.88 Cr
PE Ratio16.41
IndustryHealthcare
Company Performance:
1D-1.72%
1M+3.83%
6M+18.31%
1Y+10.01%
5Y-5.47%
View Company Insightsright
More news about Bliss GVS Pharma
05Nov 25
Bliss GVS Pharma Expands Share Capital Through Employee Stock Option Allotment
Bliss GVS Pharma Limited has allotted 33,670 equity shares to eligible employees under its Employee Stock Option Plan 2019. The allotment, approved on November 5, 2025, increases the company's total issued shares from 10,56,88,923 to 10,57,22,592. Shares were issued at an exercise price of Rs. 43.00 per share and are subject to a six-month lock-in period until May 5, 2026. This move represents a 0.03% dilution for existing shareholders and aligns with the company's strategy to incentivize employees.
29Jul 25
Bliss GVS Pharma Reports Stellar Q1 FY2026 Results, Grants Employee Stock Options
Bliss GVS Pharma announced impressive Q1 FY2026 results with net profit doubling to ₹430.00 million and revenue increasing to ₹2,070.00 million. EBITDA rose to ₹413.00 million with a margin of 19.92%. The company also approved a grant of 268,000 stock options under its Employee Stock Options Plan 2019, with an exercise price of ₹43.00 per option/share and a four-year vesting period.
13May 25
Bliss GVS Pharma Reports Impressive Q4 Turnaround with 155.4 Crore Profit
Bliss GVS Pharma Ltd. has achieved a significant financial turnaround in Q4, reporting a consolidated net profit of 155.4 crore rupees compared to a 91.5 crore rupees loss in the same quarter last year. Revenue remained stable at 198.00 crore rupees year-over-year. The company's sequential growth shows profit increased from 23.80 crore rupees in the previous quarter. Despite stable revenue, Bliss GVS Pharma demonstrated improved operational efficiency with decreased interest costs, indicating better debt management.
12May 25
Bliss GVS Pharma Reports Mixed Q4 Results: Profit Turnaround Amid EBITDA Decline
Bliss GVS Pharma posted a consolidated net profit of ₹155.40 crore in Q4, reversing a loss of ₹91.50 crore from the previous year. Revenue remained stable at ₹1,980.00 crore. However, EBITDA decreased to ₹210.90 crore from ₹283.50 crore year-over-year, with EBITDA margin contracting to 10.65% from 14.31%. The results indicate a mixed performance with profit improvement but ongoing operational challenges.
15Apr 25
Bliss GVS Pharma's U.S. Partner Secures FDA Approval for Mesalamine Suppositories
Bliss GVS Pharma's U.S. partner, Rising Pharma Holdings, received FDA approval for Mesalamine Suppositories 1000 mg. The product targets a $29 million U.S. market. This approval strengthens Bliss GVS Pharma's portfolio of differentiated products for the U.S. market and demonstrates their in-house R&D capabilities.
Bliss GVS Pharma
175.92
-3.08
(-1.72%)
1 Year Returns:+10.01%
Industry Peers
Sun Pharmaceutical
1,737.00
(-1.08%)
Divis Laboratories
6,496.50
(+0.31%)
Torrent Pharmaceuticals
3,834.30
(+0.37%)
Cipla
1,496.30
(-0.29%)
Dr Reddys Laboratories
1,265.80
(-1.38%)
Lupin
2,107.00
(-0.31%)
Zydus Life Science
917.80
(-1.08%)
Mankind Pharma
2,193.30
(-1.63%)
Aurobindo Pharma
1,211.40
(-0.54%)
Alkem Laboratories
5,566.00
(-0.55%)